Some of Sanofi’s most high-profile readouts this year can’t have made for easy reading at the French pharma’s Paris ...

On the FDA’s docket for the back half of September is Merck’s proposed subcutaneous formulation of its blockbuster cancer ...

Sanofi to present new data from 14 abstracts across multiple sclerosis at ECTRIMS 2025 congress in Barcelona, Spain ...